Global Drug-Resistant Epilepsy Market - 2023-2030

Global Drug-Resistant Epilepsy Market - 2023-2030

Global Drug Resistant Epilepsy Market reached US$ 0.78 billion in 2022 and is expected to reach US$ 1.1 billion by 2030, growing with a CAGR of 4.4% during the forecast period 2023-2030.

A third of epileptics are thought to be affected by drug resistance, however the frequency of this condition varies depending on the epilepsy syndrome, the underlying cause, and other elements including the age at which seizures first appear and the presence of concomitant neurological impairments.

The likelihood of establishing seizure freedom on a newly tested medicine reduces with an increasing number of previously unsuccessful treatments, even if drug-resistant epilepsy is not the same as being refractory to any therapeutic treatment. When two adequately administered anti-seizure drugs have failed to control seizures, patients should, whenever possible, be transferred to a comprehensive epilepsy center for targeted care and a diagnostic re-evaluation.

Dynamics

Increasing Patients with Drug Resistant Epilepsy

Drug resistance will affect around a third of epileptic patients, and 80 percent of them live in poor nations. Patients who are drug-resistant are more likely to experience psychosocial, mental, and medical morbidities, which must be treated right away to enhance their quality of life. To avoid the debilitating symptoms of drug-resistant epilepsy, early detection of drug-resistant epilepsy is crucial for optimal therapy selection.

One of the most common and incapacitating chronic neurologic illnesses, epilepsy affects 60 million people worldwide and results in 125,000 fatalities each year. In most cases of epilepsy, antiseizure medications (ASMs) are successful in reducing seizures, however, 30–40% of individuals develop treatment resistance.

Advancements in Treatment Options

In the recent decades, significant progress has been accomplished. About the minimally invasive surgery, we are really enthusiastic. This paradigm-shifting method may replace open brain surgery as the safe and efficient choice for those with drug-resistant epilepsy. The use of VNS, RNS, and DBS for neuromodulation therapy is also developing quickly.

The University of Chicago Medical Center is still developing experience in how these devices might be used most effectively for various patients, especially for those who are not candidates for reconstructive surgery. When combined with other seizure treatments, CBD oil belongs to an entirely separate class of seizure therapy and may show promise for treating drug-resistant epilepsy.

Advancements in Neuroimaging

Neuroimaging innovations have transformed the area of neuroscience and greatly influenced how epilepsy, Alzheimer's disease, stroke, and traumatic brain injury are identified and treated as well as how these disorders are understood. With the use of these technologies, researchers and medical practitioners can more precisely diagnose patients and create personalized treatment regimens by gaining an in-depth understanding of the structure and function of the brain.

The automatic detection of problems in neuroimaging data has improved thanks to the development of advanced image analysis algorithms and machine learning approaches, assisting in early diagnosis and treatment planning.

Awareness and Education

To address and manage a variety of health issues, such as epilepsy and its subcategories including drug-resistant epilepsy, increasing awareness is a crucial step. The goal of awareness campaigns is to inform the general public, medical experts, and policymakers about the condition, its effects, the therapies that are available, and the resources that are accessible to help.

The need for specialized epilepsy clinics and centers that can offer drug-resistant epilepsy patients individualized care may increase as communities and healthcare systems become more aware of the condition. As a result of increased campaigning, governments and organizations may be persuaded to support research into epilepsy, particularly that into drug-resistant epilepsy. The funding of research can encourage the creation of cures and treatments that are more efficient.

Limited Treatment Options

For patients and healthcare professionals, the limited treatment options for some medical diseases, such as drug-resistant epilepsy, can present serious difficulties. Epilepsy cases classified as drug-resistant do not respond to conventional antiepileptic medications (AEDs). Continuous seizures may result from a lack of effective treatment alternatives, which can negatively affect a person's quality of life and interfere with their ability to work, drive, and carry out daily activities.

Drug-resistant epilepsy can cause psychosocial difficulties such as anxiety, sadness, social isolation, and a sense of helplessness. For people with drug-resistant epilepsy, uncontrolled seizures can lead to mishaps, wounds, and safety issues.

Individual Variability

Individual variability, often referred to as interindividual variability, describes the variations in how people experience and manage their health conditions as well as how they respond to treatments, drugs, and interventions. This unpredictability is a key component of healthcare and has a big impact on patient care, diagnosis, and treatment planning. An important contributor to individual variability is genetics.

Gene variations can impact a person's ability to metabolize drugs, respond to treatments, and be susceptible to specific medical disorders. Each person's disease may develop in a unique way. Decisions on treatment and prognosis are impacted by variations in disease progression. For instance, every patient's experience with cancer will be unique.

Segment Analysis

The global drug-resistant epilepsy market is segmented based on treatment type, end-users, and region.

Antiseizure Medications

Approximately 30% of epilepsy patients are drug-resistant, despite the availability of numerous anti-seizure medicines (ASMs). Other non-pharmacological methods are used to treat people with epilepsy (PWE) or people who are drug-resistant, such as reconstructive surgery, vagus nerve stimulation, and dietary therapy.

These ASMs are typically advised in doses of mono-, bi-, or polytherapy depending on the forms of epilepsy diagnosed and the frequency of seizures. As first-generation ASMs, phenytoin (PHT), carbamazepine (CBZ), and sodium valproate (VPA) are frequently used to treat epilepsy.

Geographical Penetration

Advanced Healthcare Infrastructure

North America has been a dominant force in the global drug-resistant epilepsy market. According to estimates, approximately one-third of North American epileptics have drug-resistant types of the disease. There are numerous specialized epilepsy clinics and facilities throughout North America.

Neurologists and epileptologists with experience in identifying and managing drug-resistant epilepsy are employed by these facilities. In order to effectively diagnose and treat the illness, epilepsy centers in North America frequently provide cutting-edge diagnostic methods, such as video EEG monitoring and neuroimaging.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global drug resistant epilepsy market. Outpatient visits and elective procedures were among the usual healthcare services that were affected by the pandemic. Many people with drug-resistant epilepsy depend on routine exams and diagnostic testing to control their disease, yet during the height of the pandemic, these appointments were rescheduled or canceled.

Due to a lack of access to healthcare services, some people may have had delays in acquiring an accurate epilepsy diagnosis or starting treatment. Telehealth services were quickly embraced in order to solve the problems caused by the pandemic. For patients with epilepsy, including those with drug-resistant forms, neurologists and epileptologists have started conducting online consultations.

Russia-Ukraine War Impact Analysis

The conflict between Russia and Ukraine could result in population displacement and damage to the healthcare system. For those who are impacted, accessing medical care, particularly epilepsy treatment, may be difficult. Clinical trials that are still in progress and research projects aimed at finding cures for epilepsy might be impacted.

Research interruptions can hinder the creation of novel medicines and postpone the availability of cutting-edge therapeutics for drug-resistant epilepsy. During geopolitical crises, international collaborations in medical research and healthcare may be disrupted or strained. For the purpose of promoting research and enhancing drug-resistant epilepsy treatment options, collaboration is crucial.

By Treatment Type
• Neuromodulation Therapy
• Antiseizure Medications
• Benzodiazepines
• Resective Epilepsy Surgery
• Specific Metabolic Treatment
• Specific Genetic Treatment
• Immunotherapy

By End-users
• Hospitals
• Clinics
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include UCB S.A., Jazz Pharmaceuticals, LivaNova PLC, NeuroPace, Inc., Avenue Therapeutics, Xenon Pharmaceuticals Inc., and others.

Why Purchase the Report?
• To visualize the global drug-resistant epilepsy market segmentation based on treatment type, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of drug-resistant epilepsy market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global drug resistant epilepsy market report would provide approximately 44 tables, 48 figures and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies